NCT06030414View on ClinicalTrials.gov

A Study to Determine the Tolerability of Intranasal LMN-301

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

December 28, 2023

Study Completion Date

April 3, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

LMN-301

Intranasally administered powder.

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

Lumen Bioscience, Inc.

INDUSTRY